Filgrastim Biosimilars: Savings Potential Revealed
Unlocking Savings and Expanding Access: The Power of Biosimilars in Oncology
Table of Contents
The landscape of cancer treatment is rapidly evolving, with biosimilars emerging as a critical tool for enhancing patient access and reducing healthcare costs. As the oncology market continues its upward trajectory, projected to reach $300 billion by 2028, the strategic adoption of biosimilars presents a significant opportunity for healthcare systems to achieve substantial financial savings and broaden the reach of essential supportive care.
The Economic Impact of Biosimilar Adoption
The introduction of biosimilars, wich are highly similar to already approved biologic medicines, offers a cost-effective choice without compromising on efficacy or safety. A recent study highlighted the profound economic benefits of incorporating biosimilars into clinical practice. As a notable example, the use of a pegfilgrastim biosimilar (Udencya; Coherus) in a cohort of 4,000 patients across six chemotherapy cycles resulted in nearly $3 million in savings. This financial relief translated directly into expanded supportive care for 9,244 patients.
When benchmarked against the reference product,the biosimilar demonstrated even more notable savings,reaching up to $12 million and enabling supportive care for over 32,000 patients. Given that the United States population is ten times larger than that of Saudi Arabia,the potential for savings with broader biosimilar adoption is exponentially greater. Even a single biosimilar generating $15 million in savings underscores the need for pharmacists to explore larger oncology medication classes for further cost reductions.
Strategic Considerations for Biosimilar integration
while the benefits of biosimilars are clear, their triumphant integration into healthcare systems requires careful planning and execution.The process typically involves the Pharmacy and Therapeutics (P&T) committee to add biosimilars to the formulary.navigating the array of available products,each with varying prices,necessitates a thorough evaluation of key factors such as regulatory approval status,product availability,and the potential for substitution.
To streamline this selection process, healthcare institutions can benefit from implementing policies that actively promote biosimilar selection. Furthermore, developing contingency plans to address potential supply chain disruptions is crucial for ensuring uninterrupted patient care.In scenarios where both the originator biologic and its biosimilar are available at the same facility, meticulous attention to proper storage protocols is paramount to prevent the inadvertent administration of the incorrect medication.
Empowering Pharmacy Staff for Success
Ultimately, the successful adoption of biosimilars hinges on the comprehensive training and engagement of the entire pharmacy staff. By fostering trust and understanding, institutions can drive meaningful change that yields significant savings for both the organization and its patients. While the task of adding biosimilars to the formulary may seem complex, formulary management teams should proactively pursue the inclusion of appropriate biosimilars. This initiative not only reduces patient expenses but also generates substantial institutional savings, ultimately enhancing the capacity to provide vital treatments and supportive care to a larger patient population.
REFERENCES
- Global Oncology trends 2024: Outlook to 2028. IQVIA.May 28, 2024.Accessed July 18, 2025.https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-oncology-trends-2024
- Khan MA, Abu Esba LC, Yousef CC, et al. Practical challenges and considerations in adopting biosimilars in oncology clinical practice within a large healthcare system. Expert Review of Clinical Pharmacology. 2024;18(6):323-331. doi:10.1080/17512433.2025.2492063